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ABSTRACT
Objectives: To assess the extent to which stage at
diagnosis and adherence to treatment guidelines may
explain the persistent differences in colorectal cancer
survival between the USA and Europe.
Design: A high-resolution study using detailed clinical
data on Dukes’ stage, diagnostic procedures, treatment
and follow-up, collected directly from medical records
by trained abstractors under a single protocol, with
standardised quality control and central statistical
analysis.
Setting and participants: 21 population-based
registries in seven US states and nine European
countries provided data for random samples
comprising 12 523 adults (15–99 years) diagnosed
with colorectal cancer during 1996–1998.
Outcome measures: Logistic regression models
were used to compare adherence to ‘standard care’ in
the USA and Europe. Net survival and excess risk of
death were estimated with flexible parametric models.
Results: The proportion of Dukes’ A and B tumours
was similar in the USA and Europe, while that of
Dukes’ C was more frequent in the USA (38% vs 21%)
and of Dukes’ D more frequent in Europe (22% vs
10%). Resection with curative intent was more
frequent in the USA (85% vs 75%). Elderly patients
(75–99 years) were 70–90% less likely to receive
radiotherapy and chemotherapy. Age-standardised
5-year net survival was similar in the USA (58%) and
Northern and Western Europe (54–56%) and lowest in
Eastern Europe (42%). The mean excess hazard up to
5 years after diagnosis was highest in Eastern Europe,
especially among elderly patients and those with
Dukes’ D tumours.
Conclusions: The wide differences in colorectal
cancer survival between Europe and the USA in the late
1990s are probably attributable to earlier stage and
more extensive use of surgery and adjuvant treatment
in the USA.
Elderly patients with colorectal cancer received
surgery, chemotherapy or radiotherapy less often than
younger patients, despite evidence that they could also
have benefited.
ARTICLE SUMMARY
Article focus
▪ Why has population-based survival for colorectal
cancer been so much higher in the USA than in
Europe?
▪ Can differences in stage, diagnostic procedures
and/or treatment explain these wide disparities?
▪ Are evidence-based guidelines for staging and
treatment being followed?
Key messages
▪ The stage at diagnosis varied more widely
between the participating European countries
than between the participating US states.
▪ Evidence-based guidelines do not seem to have
been closely followed. The proportion of patients
who received surgery with adjuvant chemo-
therapy and/or radiotherapy was much lower in
Europe than in the USA. Elderly patients received
surgery, chemotherapy or radiotherapy less often
than younger patients, despite evidence that they
could have benefited.
▪ The wide US–Europe differences in 5-year net
survival from colorectal cancer in the late 1990s
were probably attributable to the earlier stage
and more extensive use of surgery and adjuvant
treatment in the USA. Lower survival in Europe
was mainly attributable to the much lower sur-
vival in Eastern countries. This study underlines
the need for population-based survival estimates
derived from systematic clinical records of stage
and treatment for all patients.
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INTRODUCTION
Five-year relative survival from cancers of the colon and
rectum has been reported as 12–14% higher in the USA
than in Europe.1 Survival for patients diagnosed during
1985–1989 was higher in each of the 9 US states and
metropolitan areas covered at that time by the
Surveillance, Epidemiology and End Results (SEER)
Program than in any of the 22 European countries par-
ticipating in the EUROCARE-2 study.2
The differences in 3-year colorectal cancer survival for
patients diagnosed during 1990–1991 between 10 terri-
tories in ﬁve European countries and the nine SEER
areas were mainly attributable to the stage at diagnosis.3
The ﬁrst worldwide analysis of cancer survival
(CONCORD1) provided a systematic comparison of sur-
vival for adults (15–99 years) diagnosed with cancer of
the breast, colon, rectum or prostate in 31 countries
during 1990–1994 and followed up to 1999.
International differences in age-standardised survival
were very wide, even after adjustment for differences in
mortality from other causes of death. Colorectal cancer
survival was higher in the USA and Canada than in
many other countries. Differences between the USA and
most European regions were smaller than for patients
diagnosed during 1985–1989.2 The largest differences
were between the USA and Eastern Europe.
The CONCORD protocol incorporated studies
designed to explain the international variations in sur-
vival. These ‘high-resolution’ studies involve the system-
atic collection of detailed clinical and pathological data
that are not routinely abstracted by population-based
cancer registries from the original medical records of
large random samples of patients. The high-resolution
study reported here provides a transatlantic comparison
of stage, treatment and survival for patients with colorec-
tal cancer.
The aims were (1) to compare the distributions of
stage for colorectal cancers in Europe and the USA; (2)
to determine whether the transatlantic differences in
survival persist and, if so, to assess the extent to which
they are attributable to differences in stage at diagnosis
and (3) to compare adherence to ‘standard care’4 for
colorectal cancer in relation to age, stage and cancer
site between the USA and Europe.
MATERIAL AND METHODS
Data on stage, diagnostic procedures, treatment and
follow-up were collected for a representative sample of
about 13 000 patients aged 15–99 years diagnosed with
colorectal cancer (International Classiﬁcation of
Diseases, ninth revision (ICD-9)5 codes 1530–1539,
1540–1549) in the USA and Europe during 1996–1998.
A single protocol was used, derived from the
EUROCARE high-resolution protocols.6
The European data were provided by 14 population-
based cancer registries in nine countries, four with
national coverage (denoted below with an asterisk (*)).
For some analyses, the data were grouped into the four
European regions deﬁned by the United Nations (UN,
http://unstats.un.org/unsd/methods/m49/m49regin.
htm)—Northern Europe: Finland*; Western Europe:
France (Côte d’Or) and the Netherlands (North East
Netherlands); Southern Europe: Italy (Genova, Ragusa
and Varese), Slovenia* and Spain (Granada, Navarra
and Tarragona); Eastern Europe: Estonia*, Poland
(Cracow and Kielce) and Slovakia*. Estonia is classiﬁed
by the UN as being in Northern Europe, but cancer sur-
vival has resembled that in Eastern European countries7
and Estonia was included here with Eastern Europe. US
data were provided by seven statewide registries
(California, Colorado, Illinois, Louisiana, New York,
Rhode Island and South Carolina) from the National
Program of Cancer Registries (NPCR), based at the
Centers for Disease Control and Prevention.
For this study, cancer registries in the EUROCARE-3
high-resolution study8 updated follow-up to at least
5 years after diagnosis for all patients. North East
Netherlands was not included in EUROCARE-3, but the
registry routinely collects high-resolution data and could
provide such data on virtually all patients with colorectal
cancer.
Most registries provided a random sample of at least
500 patients diagnosed during 1996–1998 (1997 in the
USA). The Finnish cases were a population-based
sample of patients diagnosed in the Tampere hospital
region, which is considered representative of Finland.
Of the 12 941 anonymised records for patients with a
malignant neoplasm of the colon or rectum, 418 were
excluded: in situ (396, 3.1%: collected in the USA, but
not in Europe); unknown sex (22, 0.2%); benign or
uncertain behaviour (1), or age less than 15 or 100 years
ARTICLE SUMMARY
Strengths and limitations of this study
▪ To our knowledge, this is the first population-based high-
resolution study with a direct US–Europe comparison of colo-
rectal cancer survival, using clinical data on investigation and
treatment collected directly from medical records by trained
abstractors with a single protocol, which was then subjected
to standard quality control procedures and analysed centrally
with the same statistical methods. Some of these clinical
records of investigation, stage and treatment are not complete,
systematic or timely because they are not collected through
routine cancer surveillance reporting for all patients with
cancer.
▪ Most of the diagnostic and therapeutic approaches used in the
late 1990s remain in widespread use; mesorectal excision for
rectal cancer is more recent. It remains relevant to understand
the extent to which investigation and treatment are responsible
for the persistent international differences in colorectal cancer
survival.
▪ The modelling approach to estimate net survival is a methodo-
logical strength.
▪ Northern Europe was represented only by Finland.
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or over (19, 1.5%). In all, 12 523 patients with a primary,
invasive and malignant colorectal neoplasm were
included in the comparisons of stage and treatment. For
survival analyses, a further 118 patients were excluded:
cancer registered only from a death certiﬁcate (72,
0.6%), unknown vital status (3, 0.02%) and date of last
known vital status either unknown or earlier than the
date of diagnosis (43, 0.3%), leaving 12 405 patients
(99.1% of the 12 523 eligible).
Information on stage, diagnostic examinations and
treatment was abstracted from the clinical record, path-
ology reports, hospital discharge records and other
sources, as necessary.
Disease stage was deﬁned according to the tumour,
nodes, metastasis (TNM) manual9 and/or Dukes’ stage.
Many registries collected TNM and Dukes’ stage, but
only Dukes’ stage was available for Kielce (Poland) and
Finland, so we used Dukes’ classiﬁcation in order to
include these populations in the stage-speciﬁc analyses.
Dukes’ stage information was more complete than that
in the TNM stage, but TNM was used to reconstruct
Dukes’ stage where necessary. For descriptive purposes,
we deﬁned patients with ‘advanced stage’ as those with
metastatic disease or those who had been operated on,
but for whom no pathology report was available. This
broad category was not used in stage-speciﬁc survival
analyses, which are based on Dukes’ stage, where
available.
Age was categorised as 15–64, 65–74 and 75–99 years.
We deﬁned resection for curative intent as resection of
all macroscopically evident malignant tissue with no
macroscopic evidence of surgical margin involvement,
excluding polypectomy and transanal excision.
Radiotherapy and chemotherapy were dichotomised as
administered versus not administered or unknown.
Statistical analysis
We analysed the distribution of stage and the number of
lymph nodes examined pathologically.9 We report the
proportion of patients resected with curative intent and
the distributions of stage-speciﬁc treatment for colon or
rectal cancer. Data sets were excluded if data on stage
and/or treatment were missing for 25% or more of
patients: Ragusa was excluded from stage-speciﬁc ana-
lyses, including those on treatment related to the stage
at diagnosis.
Net survival up to 5 years after diagnosis was estimated
by geographical area (UN region of Europe, country,
registry or US state), age and stage, using ﬂexible para-
metric excess hazard models.10 Net survival is the survival
of patients with cancer in the hypothetical situation
where the cancer may be assumed to be the only possible
cause of death; it may be interpreted as cancer survival
after controlling for competing causes of death. Net
survival was estimated with a modelling approach10–12 in
which the total hazard of death is considered as the sum
of the cancer-related mortality hazard (excess hazard)
and the hazard of death from other causes (background
hazard). The background hazard is derived from life
tables of all-cause mortality by sex, single year of age and
calendar year in the general population of the geo-
graphical area from which the patients with cancer are
drawn. We constructed period life tables for 1994–2004
with the approaches proposed by Baili et al.13
Age was included as a continuous variable in all
models, in order to avoid the bias in the estimation of
net survival that would otherwise arise from differential
loss of the oldest patients to competing hazards of death
(informative censoring). The non-linear and time-
dependent (interaction with time since diagnosis)
effects of age were initially modelled with cubic splines.
The proportionality of the effect of tumour stage on the
excess hazard was also assessed. Simpler models, with
linear and/or proportional effects, were successively
tested and selected using the Akaike information criter-
ion for goodness of ﬁt.14 We also estimated the instan-
taneous excess risk (hazard) of death due to colorectal
cancer, after subtracting the hazard from all other
causes of death.10–12 15 16 We present the mean excess
hazard per 1000 person-years at risk at selected times
since diagnosis (1 and 6 months, and 1, 3 and 5 years),
by age group as well as by stage at diagnosis, after adjust-
ment for age.
The overall (all ages) net survival estimates were age
standardised with the International Cancer Survival
Standard (ICSS) weight.17
We used a logistic regression model to estimate the
odds of patients with colorectal cancer in each area
being resected with curative intent, the odds of patients
with colon cancer at Dukes’ stage B or C receiving
chemotherapy, and the odds of patients with rectal
cancer with Dukes’ stage A–C being treated with radio-
therapy, after adjustment for age and/or tumour site
and/or sex.
Survival analyses were performed with stpm215 in Stata
V.12 (StataCorp LP, College Station, Texas, USA).
RESULTS
We included 12 523 patients with an invasive, primary
colorectal cancer: 9186 patients in 14 registries in nine
European countries and 3337 patients in seven US states
(table 1). Microscopic veriﬁcation was available for 96–
98% of the patients in each of the US states and 93% in
Europe, ranging from 85% in Ragusa (Italy) to 99% in
Kielce (Poland). The proportion of patients with colo-
rectal cancer who were men was similar in Europe
(53%) and the USA (50%), but colon cancer was more
frequent in the USA (73%) than in Europe (60%). Data
were available on stage at diagnosis for 90–93% of
patients on both sides of the Atlantic, ranging from 76%
(Finland) to 95% or more in 3 of the 14 European regis-
tries and from 90% (Colorado and South Carolina) to
97% (Louisiana) in the USA.
Early-stage (Dukes’ A or B) colorectal cancers were
equally common in the USA (45%) and Europe (47%),
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Table 1 Calendar period of diagnosis, morphological verification and data on sex, cancer site and stage. Patients with invasive primary colorectal cancer, Europe and the USA
Dukes’ stage at diagnosis*
Microscopically
verified Males Colon A B C D
Not
available
EUROPE Registry N
Period of
diagnosis N % N % N % N % N % N % N % N %
Estonia Estonia 560 1997 491 88 250 45 337 60 144 26 151 27 76 14 167 30 22 4
Finland Finland 523 1996–1998 478 91 247 47 294 56 61 12 174 33 103 20 60 11 125 24
France Côte d’Or 561 1996–1997 544 97 302 54 382 68 112 20 209 37 98 17 114 20 28 5
Italy Genova 589 1996 529 90 326 55 379 64 71 12 192 33 148 25 131 22 47 8
Ragusa† 424 1996–1998 361 85 233 55 269 63
Varese 500 1997 485 97 266 53 332 66 109 22 148 30 105 21 114 23 24 5
Netherlands North East Netherlands 1936 1997 1821 94 1002 52 1240 64 280 14 579 30 463 24 332 17 282 15
Poland Cracow 512 1997–1998 463 90 252 49 285 56 128 25 101 20 82 16 158 31 43 8
Kielce 271 1996 267 99 147 54 133 49 62 23 67 25 41 15 89 33 12 4
Slovakia Slovakia 581 1996 535 92 351 60 315 54 161 28 147 25 75 13 160 28 38 7
Slovenia Slovenia 937 1997 871 93 490 52 474 51 131 14 265 28 243 26 209 22 89 9
Spain Granada 567 1996–1997 523 92 312 55 360 63 63 11 191 34 109 19 148 26 56 10
Navarra 588 1996–1997 558 95 354 60 335 57 100 17 188 32 121 21 120 20 59 10
Tarragona 637 1996–1997 603 95 339 53 421 66 71 11 174 27 176 28 146 23 70 11
European registries‡ 9186 8529 93 4871 53 5556 60 1493 17 2586 30 1840 21 1948 21 895 10
Northern Europe 523 478 91 247 47 294 56 61 12 174 33 103 20 60 11 125 24
Western Europe 2497 2365 95 1304 52 1622 65 392 16 788 32 561 22 446 18 310 12
Southern Europe† 4242 3930 93 2320 55 2570 61 545 14 1158 30 902 24 868 20 345 8
Eastern Europe 1924 1756 91 1000 52 1070 56 495 26 466 24 274 14 574 30 115 6
USA
California 495 1997 485 98 242 49 356 72 89 18 137 28 168 34 60 12 41 8
Colorado 548 1997 536 98 296 54 407 74 85 16 162 30 191 35 56 10 54 10
Illinois 505 1997 497 98 239 47 384 76 71 14 144 29 224 44 36 7 30 6
Louisiana 511 1997 502 98 263 51 374 73 115 23 146 29 146 29 90 18 14 3
New York 492 1997 473 96 248 50 350 71 91 18 114 23 226 46 21 4 40 8
Rhode Island 418 1997 413 99 195 47 302 72 64 15 149 36 160 38 29 7 16 4
South Carolina 368 1997 358 97 187 51 265 72 68 18 89 24 150 41 26 7 35 10
US registries 3337 3264 98 1670 50 2438 73 583 17 941 28 1265 38 318 10 230 7
Total 12523
*Dukes’ stage A–D correspond to TNM stage categories I-IV.
†Data for Ragusa are not included in the percentages of Dukes' stage for Southern Europe.
‡Northern Europe: Finland; Western Europe: France (Côte d'Or), the Netherlands (North East Netherlands); Southern Europe: Italy (Genova, Ragusa, Varese), Slovenia, Spain (Granada,
Navarra, Tarragona); Eastern Europe: Estonia, Poland (Cracow, Kielce), Slovakia.
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but the stage distributions varied widely between the US
states and between the European regions. Tumours in
Dukes’ stage A were of similar frequency in Europe (17%,
range 11–28%) and in the USA (17%, 14–23%), and the
proportion of Dukes’ B tumours were also very compar-
able (Europe 30%, 25–37%; USA 28%, 24–36%). In con-
trast, Dukes’ C tumours were twice as common in the
USA (38%, 29–46%) as in Europe (21%, 24–30%), while
Dukes’ D tumours were twice as common in Europe
(21%, 11–33%) as in the USA (10%, 7–18%). The pro-
portion of tumours with unspeciﬁed stage was slightly
higher in Europe (10%, 4–24%) than in the USA (7%,
3–10%). Exclusion of Finland, with 24% of tumours of
unknown stage, did not substantially alter the overall
stage distributions in Europe (data not shown).
Patients diagnosed at an advanced stage (ie, metastatic
cases plus unresected cases for which no data on stage
were available) were more common in the four European
regions (29%, 24–34%) than in the USA (20%, 16–23%;
table 2). In Europe, advanced stage was more common in
Southern Europe (30%) and Eastern Europe (34%). The
highest proportion of patients at an advanced stage in
the USA (23%, California) was similar to the lowest
regional proportion in Europe (24%, Western Europe).
Resection for curative intent was more frequent in the
USA (85%) than in Europe (75%). The proportion
resected with curative intent was remarkably similar in
all seven US states (84–88%). Only Western Europe
(84%) showed a proportion as high as that in the USA.
Thirty-day postoperative mortality was 5% or less in
the USA and Europe. Among patients resected with
curative intent, the proportion with a known stage was
around 95% in the USA and Europe, with the lowest
proportions in Northern Europe (84–90%; table 2). In
many European registries, data on the number of lymph
nodes examined after surgery were not available for
most patients (see web-appendix table S1).
Adjuvant chemotherapy and radiotherapy were adminis-
tered more frequently in the USA than in Europe (table
3). Among Dukes’ B patients with colon cancer, 28%
received chemotherapy in the USA (21–46%) vs 20% in
Europe (4–31%). Among Dukes’ C patients with colon
cancer, 56% received chemotherapy in the USA (47–
64%) vs 47% in Europe (38–53%). Among Dukes’ A–C
patients with rectal cancer, 47% received radiotherapy in
the USA (41–52%) vs 37% in Europe (26–45%).
Relative to Southern Europe (2912 patients, reference
category), the odds of receiving resection for curative
intent (vs any other surgical procedure), after adjust-
ment for age and tumour site, were much lower in
Eastern Europe (OR 0.46, 95% CI 0.41 to 0.52), some-
what lower in Northern Europe (OR 0.88, 0.71 to 1.09)
and much higher in Western Europe (OR 1.62, 1.43 to
1.85) and in the USA (OR 1.72, 1.52 to 1.94; table 4).
Table 2 Advanced stage, resection with curative intent, 30-day postoperative mortality and proportion of patients with
information on stage: colorectal cancer, Europe and the USA, 1996–1998
All cases Resected with curative intent*
Advanced
stage†
Deaths
within
30 days Staged
Colon Rectum
EUROPE Registry N N % N % N % N % N %
European registries‡ 8762 2535 29 6584 75 248 4 3895 95 2374 95
Northern Europe 523 134 26 385 74 16 4 192 84 142 90
Western Europe§ 2497 609 24 2092 84 24 6 1299 93 646 92
Southern Europe¶ 3818 1131 30 2912 76 152 5 1748 97 1081 97
Eastern Europe 1924 661 34 1195 62 56 5 656 98 505 97
US registries 3337 676 20 2832 85 124 4 2039 97 677 93
California 495 112 23 415 84 15 4 294 96 102 93
Colorado 548 113 21 468 85 18 4 335 95 109 93
Illinois 505 112 22 422 84 21 5 320 97 85 93
Louisiana 511 105 21 431 84 26 6 315 100 111 97
New York 492 80 16 411 84 22 5 287 95 102 94
Rhode Island 418 78 19 369 88 9 2 268 99 93 94
South Carolina 368 76 21 316 86 13 4 220 96 75 87
Total 12 099
†All metastatic cases, plus unresected cases for which no stage data were available.
*Curative intent: surgery not specified as palliative or tumour entirely resected.
‡Northern Europe: Finland; Western Europe: France (Côte d’Or) and the Netherlands (North East Netherlands); Southern Europe: Italy
(Genova, Ragusa and Varese), Slovenia and Spain (Granada, Navarra and Tarragona); Eastern Europe: Estonia, Poland (Cracow and Kielce)
and Slovakia.
§Data for North East Netherlands (1936) are not included in the proportion of deaths within 30 days of surgery for Western Europe because
the date of surgery was not available.
¶Data for Ragusa (424) are not included in the percentages of Dukes’ stage for Southern Europe.
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Patients aged 75 years or more were only half as likely
to be resected with curative intent as those aged 15–
64 years (OR 0.48, 95%CI 0.43 to 0.53), after adjustment
for region and tumour site.
Patients with colon cancer (reference category) were
resected with curative intent more often than patients
with rectal cancer (OR 0.73, 0.66 to 0.79).
Patients with Dukes’ B colon cancer received chemo-
therapy much less often in Western Europe (OR 0.10,
0.06 to 0.16) and Northern Europe (OR 0.29, 0.15 to
0.56) than in Southern Europe. For patients with Dukes’
C colon cancer, chemotherapy was used less in Western
Europe (OR 0.64, 0.48 to 0.87) and more often in the
USA (OR 1.56, 1.23 to 1.98) than in Southern Europe.
Radiotherapy was administered to patients with rectal
cancer in Dukes’ stage A–C more often in the USA (OR
1.39, 1.10 to 1.76) and less often in Northern Europe
(OR 0.58, 0.38 to 0.89) or Eastern Europe (OR 0.46,
0.36 to 0.59), compared to Southern Europe.
Older patients were only 10% as likely to be treated
with radiotherapy and chemotherapy.
Overall, age-standardised net survival at 5 years was
50% in Europe and 58% in the USA (ﬁgure 1). Survival
was lower in all European areas than in the USA, and
only in Northern Europe was the ﬁgure (56%) close to
that in the USA. Survival was lower in Western Europe
(54%) and in Southern Europe (49%) and lowest in
Eastern Europe (42%). Survival varied widely not only
between European countries (from 56% in France and
Finland to 37% in Poland), but also between US states
(from 64% in Rhode Island to 56% in Illinois and 50%
in South Carolina).
Five-year age-standardised net survival was higher in
the USA than in Europe for Dukes’ stage A (84%) and
B (75%) tumours, but higher in Northern Europe than
in the USA for Dukes’ C (52%) and D (12%) tumours
(ﬁgure 2). The geographical range in survival was much
wider for locally advanced disease, from 36% in Eastern
Europe to 77% in Northern Europe and 49% in the
USA. As with overall survival, stage-speciﬁc 5-year survival
was similar in Northern, Western and Southern Europe
and the USA. In Eastern Europe, survival for node-
positive, locally advanced and metastatic tumours was
lower than in other European regions and the USA.
Survival was 5–12% higher in women than in men in
all areas, especially in Northern and Western Europe
(11–12%; see web-appendix ﬁgure S1).
The mean excess hazard of death at 1 and 6 months,
and at 1, 3 and 5 years after diagnosis was higher in
Eastern Europe than in all other regions, for all ages
combined as well as in each of the three age categories
(see web-appendix ﬁgure S2). The difference was most
marked for elderly patients (75–99 years). No striking
differences were found between Northern, Western and
Southern Europe and the USA. The high excess hazard
of death in Eastern Europe was mainly conﬁned to
patients with Dukes’ D tumours (see web-appendix
ﬁgure S3).
DISCUSSION
Transatlantic differences in population-based colorectal
cancer survival have raised questions about early diagno-
sis and the adequacy of investigation and treatment that
cannot be addressed with data from clinical trials, which
include only selected patient groups.
Patterns-of-care studies and survival studies have been
conducted separately in Europe3 6 8 and the USA.18 19
Table 3 Chemotherapy in Dukes’ B and C colon cancer and radiotherapy in Dukes’ A–C rectal cancer
Colon Dukes’ B* Colon Dukes’ C* Rectum Dukes’ A–C*
N
Among whom,
chemotherapy N
Among whom,
chemotherapy N
Among whom,
radiotherapy
EUROPE Registry N % N % N %
European registries† 1748 343 20 1130 528 47 1850 678 37
Northern Europe 110 11 10 50 21 42 118 34 29
Western Europe 591 23 4 346 133 38 411 183 45
Southern Europe‡ 736 209 28 529 265 50 797 331 42
Eastern Europe 259 80 31 154 81 53 480 124 26
US registries 727 200 28 913 508 56 484 228 47
California 108 29 27 114 54 47 65 31 48
Colorado 129 29 22 145 93 64 70 29 41
Illinois 112 28 25 171 88 51 65 33 51
Louisiana 105 22 21 106 59 56 76 33 43
New York 86 24 28 157 81 52 84 44 52
Rhode Island 119 37 31 107 69 64 66 30 45
South Carolina 68 31 46 113 64 57 58 28 48
*Dukes’ stage A–D correspond to TNM stage categories I–IV.
†Northern Europe: Finland; Western Europe: France (Côte d’Or) and the Netherlands (North East Netherlands); Southern Europe: Italy
(Genova, Ragusa and Varese), Slovenia and Spain (Granada, Navarra and Tarragona); Eastern Europe: Estonia, Poland (Cracow and Kielce)
and Slovakia.
‡Data for Ragusa (424) are not included in the percentages of Dukes’ stage for Southern Europe.
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To our knowledge, this is the ﬁrst population-based high-
resolution study that allows direct comparison of colo-
rectal cancer survival between Europe and the USA with
clinical data on investigation and treatment collected
directly from medical records by trained abstractors with
a single protocol, which is then subjected to standard
quality control procedures and analysed centrally with
the same statistical methods.
The participating cancer registries are population-
based registries that register all persons diagnosed in the
territory they cover. This study included large, randomly
selected subsets of all persons diagnosed with colorectal
cancer during 1996–1998 in each territory. These
samples are not intended to be ‘representative’ of all
patients with colorectal cancer in Europe or the USA,
but they are representative of all patients with colorectal
cancer diagnosed during 1996–1998 in the territory of
each registry and the ﬁndings are generalisable to the
populations from which they are drawn.
Most of the diagnostic and therapeutic approaches
used in the late 1990s remain in widespread use.
Understanding their role in international differences in
survival remains relevant. Mesorectal excision for rectal
cancer is the main exception: it has improved survival
from rectal cancer20 21 but its widespread use is more
recent. Mesorectal excision was not used in Estonia
before 1997, which may partly explain the low survival
from rectal cancer.22
The transatlantic 12% difference in the 3-year survival in
colorectal cancer survival for patients diagnosed during
1990–19913 was mostly attributed to the differences in
stage at diagnosis. In our study of patients diagnosed in
the late 1990s, the overall 5-year net survival was still
higher in the 7 US states (58%) than in the 14 European
regions (42–56%). The widest differences with the USA
were seen in Southern (49%) and Eastern Europe (42%).
The two studies differed in design, however: data from
the SEER public-use data set in the USA23 were simply
adapted to the EUROCARE-2 high-resolution protocol
as far as possible. In contrast, data for this study were col-
lected directly from clinical records on both sides of the
Atlantic, with a standard protocol. US coverage changed
from the ﬁve metropolitan areas and four states covered
by the SEER Program to seven of the state-wide NPCR
registries. In the earlier study, differences in background
mortality in the USA were controlled with a single
national life table for 1990, weighted for the proportion
of African-American patients, white patients and other
races. Here, we were able to use state-speciﬁc life tables
for each of the calendar years 1996–2004.
The tighter control for background mortality and the
modelling approach used to estimate net survival are the
methodological strengths of this study, but these
changes do not explain why the transatlantic differences
we observed in 5-year survival are smaller than the differ-
ences in 3-year survival for patients diagnosed in the
early 1990s.3
Survival varied widely not only among European coun-
tries, but also between the seven US states. Survival in
Slovenia was lower than in other Southern European
Table 4 Odds of colorectal cancer patients with cancer being resected with curative intent, odds of patients with Dukes’ B or
C colon cancer being treated with chemotherapy and odds of Dukes’ stage A–C rectal cancer being treated with radiotherapy:
by region, age, cancer site or sex
Resection for curative
intent Colon Dukes’ B* Colon Dukes’ C* Rectum Dukes’ A–C*
N OR 95%CI N OR 95%CI N OR 95%CI N OR 95%CI
Region†
Northern Europe 385 0.88 0.71 1.09 110 0.29 0.15 0.56 50 0.88 0.46 1.69 118 0.58 0.38 0.89
Western Europe 2092 1.62 1.43 1.85 591 0.10 0.06 0.16 346 0.64 0.48 0.87 411 1.22 0.95 1.56
Southern Europe‡ 2912 1.00 736 1.00 529 1.00 797 1.00
Eastern Europe 1195 0.46 0.41 0.52 259 0.89 0.64 1.23 154 0.89 0.61 1.32 480 0.46 0.36 0.59
USA 2832 1.72 1.52 1.94 727 1.25 0.97 1.60 913 1.56 1.23 1.98 484 1.39 1.10 1.76
Age (years)
15–64 3194 1.00 674 1.00 684 1.00 890 1.00
65–74 3195 0.89 0.79 0.99 797 0.61 0.48 0.77 653 0.47 0.37 0.59 784 0.69 0.57 0.84
75–99 3027 0.48 0.43 0.53 952 0.07 0.05 0.10 655 0.10 0.08 0.13 616 0.30 0.24 0.38
Site
Colon 6191 1.00
Rectum 3225 0.73 0.66 0.79
Sex
Male 1324 1.00
Female 966 0.92 0.77 1.10
*Dukes’ stage A–D correspond to TNM stage categories I–IV.
†Northern Europe: Finland; Western Europe: France (Côte d’Or) and the Netherlands (North East Netherlands); Southern Europe: Italy
(Genova, Ragusa and Varese), Slovenia and Spain (Granada, Navarra and Tarragona); Eastern Europe: Estonia, Poland (Cracow and Kielce)
and Slovakia.
‡Data for Ragusa (424) are not included in the percentages of Dukes’ stage for Southern Europe
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countries and more similar to that in Eastern Europe. In
the USA, survival was lowest in South Carolina, where
African-American patients represent approximately 30%
of the population (http://www.ipspr.sc.edu/publication/
Older%20SC.pdf).
Apart from patients with Dukes’ B cancers, where sur-
vival was similar in Northern, Western and Southern
Europe, stage-speciﬁc net survival was rather variable.
Survival was highest in the USA for Dukes’ stage A and
B and in Northern Europe (Finland) for Dukes’ stage C
and D. This could be due to some misclassiﬁcation of
stage in Finland, where the stage data were not available
for 24% of cases.
The mean excess hazard of death up to 5 years after
diagnosis was similar in Europe and the USA for patients
with tumours in Dukes’ stage A or B. The hazard was
somewhat higher in Eastern Europe for Dukes’ stage C
and much higher for Dukes’ D disease, especially in the
ﬁrst 3 years after diagnosis. The very high hazard of
death for patients with late-stage disease in Eastern
Europe suggests that fewer effective treatment options
were available for these patients, although higher levels
of comorbidity may also have restricted the choice.
It was not possible to evaluate the impact of the
number of examined lymph nodes on the stage-adjusted
excess hazard of death, because information on nodal
status was so often unavailable (see web-appendix). It is
therefore impossible to assess whether stage migration
affects the comparison of stage-speciﬁc survival between
European regions and the USA in the late 1990s, as
reported for patients diagnosed in 1990.3
We did not have information on whether or not
patients in this study had undergone faecal occult blood
testing or sigmoidoscopy before diagnosis. Opportunistic
testing with these procedures was common in the USA
in the late 1990s. Almost 40% of respondents to the
Behavioural Risk Factor Surveillance System (http://
www.cdc.gov/mmwr/preview/mmwrhtml/00056494.
htm) survey in 1997 reported having had a faecal occult
blood test at some time in the past and 42% reported a
previous sigmoidoscopy or proctoscopy. Removal of pre-
malignant polyps or in situ neoplasms may thus have
been more frequent than in Europe. This would be
expected to reduce incidence, shift the spectrum of
malignancy to the right and reduce survival in the USA.
In fact, incidence in the USA is higher, the stage distri-
bution is less advanced, and survival is higher than in
Europe.
Adjuvant chemotherapy for colon cancer and adjuvant
radiotherapy for rectal cancer were used more widely in
the USA than in Europe. Despite the evidence available
in the late 1990s on the lack of efﬁcacy of adjuvant
chemotherapy for Dukes’ B colon cancer, 30% of
patients with colon cancer received it in the USA, and
Figure 1 Five-year age standardised net survival (%), patients diagnosed with primary invasive colorectal cancer in Europe and
the USA in the late 1990s: country and region. Note—Northern Europe: Finland; Western Europe: France (Côte d’Or) and the
Netherlands (North East Netherlands); Southern Europe: Italy (Genova, Ragusa and Varese), Slovenia and Spain (Granada,
Navarra and Tarragona); Eastern Europe: Estonia, Poland (Cracow and Kielce) and Slovakia.
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20% overall in Europe. In Finland and Western Europe,
however, adjuvant chemotherapy was rare, in line with
the contemporary recommendations, while in Southern
and Eastern Europe, adjuvant chemotherapy was used as
frequently as in the USA.
In contrast, there were striking differences in the use
of adjuvant chemotherapy for Dukes’ C stage colon
cancer in the late 1990s, particularly within Europe.
Given the wide consensus on its effectiveness since 1990,
we did not expect to ﬁnd that such a strong recommen-
dation would be so poorly followed. Comorbidity and
greater toxicity are not valid reasons for the underuse of
adjuvant chemotherapy in the elderly: toxicity is not
greater24 25 and quality of life is not worse.26
Elderly patients were 90% less likely to receive adju-
vant chemotherapy than younger patients. Clinical atti-
tudes appear to differ between the USA and Europe,
where the proportion of patients receiving adjuvant
chemotherapy is much lower. This suggests that a higher
proportion of older patients with Dukes’ C colon cancer
who are ﬁt enough to undergo surgery should receive
adjuvant chemotherapy, particularly in Europe.
Radiotherapy is known to be an effective complement
to surgery for rectal cancer, in particular to reduce the
risk of local recurrence; preoperative radiotherapy is
preferable to postoperative radiotherapy27 and it is
recommended in Europe and the USA.28–31 We were
unable to distinguish between the impact of preopera-
tive and postoperative radiotherapy, because this infor-
mation was not systematically available, but fewer
patients received radiotherapy in Europe than in the
USA and the practice in Europe was strikingly heteroge-
neous, even within a given country. Age was a strong
predictor of the use of radiotherapy. Some older patients
are unsuitable for radiotherapy because of comorbidity,
but their 70% lower odds of receiving it cannot be
explained by comorbidity alone; radiotherapy has not
yet been deployed to its full potential for older patients
with rectal cancer. It is not clear why the evidence on
the beneﬁts of radiotherapy was so poorly followed in
many regions.
Surgical resection offers the only approach to a deﬁni-
tive cure for colorectal cancer. The proportion of
patients resected with curative intent was very similar in
the seven US states (84–88%), but it varied widely
between the nine European countries (from 56% to
86%) and was particularly low in Eastern Europe (mean
62%). A more aggressive approach to surgical treatment
for elderly patients with colorectal cancer in Europe
could improve this situation, although European
patients were more often diagnosed at an advanced
stage or with unresectable disease. Performance status
and comorbidity can inﬂuence whether a patient is con-
sidered ﬁt for resection, but data on these factors were
not available. The quality of life in Canadian patients
aged over 80 years who underwent surgery for colorectal
cancer was generally comparable to that of younger
patients.32
In this large, population-based study in Europe,
however, age alone often seems to have been a limiting
factor in the treatment of colorectal cancer. Elderly
patients were generally treated less often with surgery,
chemotherapy or radiotherapy, despite the evidence that
they could beneﬁt from these treatments. Treatment
decisions should be taken in the context of multidiscip-
linary meetings, including a comprehensive geriatric
assessment: age alone should not exclude a patient from
receiving surgery and/or adjuvant treatment.
Differences in colorectal cancer survival between
Europe and the USA in the late 1990s were still wide
and may be attributable to the earlier stage at diagnosis,
higher levels of surgery and more extensive use of adju-
vant treatment in the USA.
Evidence-based guidelines do not seem to have been
followed as closely as they should be: chemotherapy was
used too often for Dukes’ B disease and not often
enough for Dukes’ C disease, especially among elderly
patients.
The need for population-based survival estimates
derived directly from the clinical records on the stage at
diagnosis and treatment is recognised by clinicians and
epidemiologists. A recent comparison of stage-speciﬁc
cancer survival with population-based data33 was compli-
cated by inconsistent coding of the stage34; several regis-
tries had to be excluded because fewer than half the
tumour records contained data on stage. In this high-
resolution study, the stage data were remarkably com-
plete (76–94% in Europe and 93% in the USA),
because they were collected directly from clinical
records. Ideally, the medical records of patients with
cancer would systematically include data on
Figure 2 Five-year age-standardised net survival (%),
patients diagnosed with primary invasive colorectal cancer in
Europe and the USA in the late 1990s: region* and stage at
diagnosis. *Northern Europe: Finland; Western Europe:
France (Côte d’Or) and the Netherlands (North East
Netherlands); Southern Europe: Italy (Genova, Ragusa and
Varese), Slovenia and Spain (Granada, Navarra and
Tarragona); Eastern Europe: Estonia, Poland (Cracow and
Kielce) and Slovakia.
Allemani C, Rachet B, Weir HK, et al. BMJ Open 2013;3:e003055. doi:10.1136/bmjopen-2013-003055 9
Open Access
investigations and stage at diagnosis; cancer registries
would obtain those data for all patients and the stage
would be coded consistently. Until then, high-resolution
studies would appear to offer the most reliable approach
to obtain data on stage and treatment, and to assess sur-
vival by stage at diagnosis.
If good evidence is required on whether all patients
receive guideline-compliant investigation and treatment,
and whether this makes a difference to survival, then
cancer registries will need to be able to obtain timely
and high-quality data on the investigations, the stage
and the treatment for all patients with cancer.
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